Некоторые нейробиологические аспекты патогенеза тревожной депрессии и антиглюкокортикоидная фармакотерапия
Рекомендуемое оформление библиографической ссылки:
Узбеков М.Г., Максимова Н.М. Некоторые нейробиологические аспекты патогенеза тревожной депрессии и антиглюкокортикоидная фармакотерапия // Российский психиатрический журнал. 2018. №2. С. 31-39.
В работе на основании собственных клинических, биохимических и гормональных исследований предложен возможный механизм взаимосвязи и взаимодействии моноаминергических и гормональной (кортизол) систем в патогенетических механизмах тревожной депрессии. Рассматривается возможность применения антиглюкокортикоидных соединений в терапии депрессии.
Ключевые слова тревожная депрессия, моноамины, кортизол, антиглюкокортикоид, патогенез
1. Goodvin FK, Jamison KR. Maniac depressive illness: bipolar disorders and recurrent depression. 2nd ed. New York: Oxford University Press; 2007. 2. Kessler RC, Ustün TB. (Eds.). The WHO World Mental Health Surveys: Global perspectives on the epidemiology of mental disorders. New York: Cambridge University Press; 2008. 3. Kupfer D. Depression: a major contributor to world-wide disease burden. International Medical News. 1999;99(2):1-2. 4. Spinney L. European Brain Policy Forum: Depression and the European Society. European Psychiatry. 2009;24(8):550-1. 5. Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, Maier SF, Yirmiya R. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry. 2014 Jun;19(6):699-709. doi: 10.1038/mp.2013.155. 6. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006 Jun;9(2):87-98. 7. Krasnov VN. [Problems of current diagnosis of depression]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. Special issues. 2012;112(11):3-10. Russian. 8. World Health Organization. Composite International Diagnostic Interview (CIDI). Version I.O. Geneva. 1999. 9. Hamilton M. Distinguishing between anxiety and depressive disorders. In: Handbook of Anxiety Disorders. Last CA, Hersen M. (Eds.) Oxford: Pergamon Press; 1988. P. 143-155. 10. Rodney J, Prior N, Cooper B, Theodoros M, Browning J, Steinberg B, Evans L. The comorbidity of anxiety and depression. Austral and New Zealand J Psychiatry. 1997;31(5):700-3. 11. Kasper S. Depression and Anxiety – Separate or Continuum? World J Biol Psychiatry. 2001;2(4):162-163. Doi: 10.3109/15622970109026804 12. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety. 2000;12(1):2-19. 13. Nuller JU, Mihalenko IA. Affektivnye psihozy. Leningrad: Nauka, 1988. 14. Laakmann G. Psychopharmacoendocrinology and depressive research. Berlin: Springer; 1991. 15. Jahn H. Steroid-synthesis inhibition in depression: a good idea? Lancet Psychiatry. 2016;3(2):92-3. 16. Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety. 2009;26(7):641-9. doi: 10.1002/da.20546. 17. Maksimova NM, Vertogradova OP. [The dynamics of anxious depression under the treatment with antidepressants with different mechanisms of action]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. Special issues. 2012;112(11):41-7. Russian. 18. Uzbekov MG, Misionzhnik EY, Maximova NM, Vertogradova OP. Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action. Hum Psychopharmacol. 2006 Mar;21(2):109-15. PMID: 16342231; doi:10.1002/hup.749 19. Moin VM, Misionzhnik JeJu, Kuznecova ZI, Gryzunov JuA, Kirkovskij VV, Uzbekov MG, Zubovskij DI. Nekotorye harakteristiki metoda i reaktivov dlja fluorescentnogo opredelenija jeffektivnoj i obwej koncentracii syvorotochnogo al'bumina. Klin. Lab. Diagnostika. 1994;(5):33-5. Russian. 20. Uzbekov MG, Maximova NM. The relationship between monoaminergic and hormonal systems and endogenous intoxication in mixed anxietydepressive disorder. Neurochemical J. 2014;8(4):311-8. 21. Holsboer F. Antidepressant drug discovery in the postgenomic era. World J Biol Psychiatry. 2001 Oct;2(4):165-77. PMID: 12587145 22. Gromova EA. Funkcional'naja vzaimosvjaz' kateholaminergicheskoj i serotoninergicheskoj sistem v golvnom mozge – antagonizm ili reciproknost'? In: Eds Turpaev TM, Budancev AJu. Kateholaminergicheskie nejrony. Moscow: Nauka; 1979: 97-105. Russian. 23. Petty F, Davis LL, Kabel D, Kramer GL. Serotonin dysfunction disorders: a behavioral neurochemistry perspective. J Clin Psychiatry. 1996;57(8):11-6. 24. Paul SM. Anxiety and depression: a common neurobiological substrate? J Clin Psychiatry. 1988 Oct;49 Suppl:13-6. PMID: 2844736 25. Belzung C. Innovative drugs to treat depression: Did animal models fail to be predictive or did clinical trials fail to detect effects? Neuropsychopharmacology. 2014 Apr;39(5):1041–1051. Doi: 10.1038/npp.2013.342. PMID: 24345817 26. Hoffman KL. Role of murine models in psychiatric illness drug discovery: a dimensional view. Expert Opin Discov. 2013;8(7):865-77. Doi:10.1517/17460441.2013.797959 27. Lapin IP. Stress – Trevoga – Depressija – Alkogolizm – Epilepsija (Nejrokinureninovye mehanizmy i novye podhody k lecheniju). Sankt-Peterburg: DEAN; 2004. 28. Curzon G. Tryptophan pyrrolase – a biochemical factor in depressive illness. Br J Psychiatry. 1970 May;116(534):571-2. PMID: 5449143 29. Uzbekov M. The hyperkinetic syndrome as a manifestation of a developmental disturbance of brain monoaminergic systems. In: Attention-Deficit/Hyperactivity Disorder and the Hyperkinetic Syndrome (HKS): Current Ideas and Ways Forward. Ed. RD. Oades. New York: Nova Science Publishers 2006: 133-154. 30. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new 5-HT hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):702-21. Doi: 10.1016/j.pnpbp.2010.12.017. 31. Syrejshchikova NI, Smolina NV, Komar AA, Gryzunov JuA, Uzbekov MG, Misionzhnik EJ, Maksimova NM. Subnanosecond Fluorescence Spectroscopy of Human Serum Albumin as a Method to Estimate the Efficiency of the Depression Therapy. Laser Physics. 2010;20(5):1074-8. 32. Nemeth S. The effect of stress or glucose feeding on hepatic tyrosine aminotransferase activity and liver and plasma tyrosine levels of intact and adrenalectomized rats. Horm Metab Res. 1978 Mar;10(2):144-7. 33. Stahl SM. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol Bull. 1985;21(3):663-71. PMID: 2863850 34. Chen K, Wu HF, Shih JC. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase are identical. J Neurochem. 1993 Jul;61(1):187-90. 35. Gorkin VZ. Aminoksidazy i ih znachenie v medicine. Moscow: Medicina; 1981. Russian. 36. Uzbekov MG, Misionzhnik JeJu, Maksimova NM, Vertogradova OP, Ryzhov AM, SHihov SN. Nekotorye aspekty metabolicheskih narushenij pri trevozhnoj depressii. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2003;(6):58-62. Russian. 37. Uphouse L. Pharmacology of serotonin and female sexual behavior. Pharmacol Biochem Behav. 2014 Jun; 0: 31–42. Published online 2013 Nov 15. doi: 10.1016/j.pbb.2013.11.008 38. Hull EM, Lorrian DS, Du J, Matuszewich L, Lumley LA, Putnam SK, Moses J. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav Brain Res. 1999 Nov 1;105(1):105-16. 39. Jørgensen HS. Studies on the neuroendocrine role of serotonin. Dan Med Bull. 2007 Nov;54(4):266-88. 40. Zarouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009 Jul;15(4):289-305. doi: 10.1097/01.pra.0000358315.88931.fc. 41. Wolkowitz OM, Reus VI, Chan T. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry. 1999 Apr 15;45(8):1070-4. 42. Thakore JH, Dinan T. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry. 1995 Mar 15;37(6):364-8. 43. Jahn H, Schick M, Kiefer F. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004 Dec;61(12):1235-44. PMID: 15583115. doi: 10.1001/archpsyc.61.12.1235 44. Drevets W.C., Price J.L., Bardgett M.E. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002 Mar;71(3):431-47. PMID: 11830178 45. Gallagher P, Young AH. Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications. Neuropsychiatr Dis Treat. 2006 Mar;2(1):33-42. PMID: 19412444 46. Howland RH. Mifepristone as a therapeutic agent in psychiatry. J Psychosoc Nurs Ment Health Serv. 2013 Jun;51(6):11-4. PMID: 23814820
DOI: http://dx.doi.org/10.24411/1560-957X-2018-1%25x
Метрики статей
Metrics powered by PLOS ALM